Pfizer Inc. (PFE)
NYSE: PFE · Real-Time Price · USD
25.52
-0.13 (-0.51%)
At close: Jan 20, 2026, 4:00 PM EST
25.52
0.00 (0.00%)
After-hours: Jan 20, 2026, 6:05 PM EST
Pfizer Revenue
Pfizer had revenue of $16.65B in the quarter ending September 28, 2025, a decrease of -5.92%. This brings the company's revenue in the last twelve months to $62.79B, up 3.89% year-over-year. In the year 2024, Pfizer had annual revenue of $63.63B with 6.84% growth.
Revenue (ttm)
$62.79B
Revenue Growth
+3.89%
P/S Ratio
2.32
Revenue / Employee
$775,123
Employees
81,000
Market Cap
145.10B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 63.63B | 4.07B | 6.84% |
| Dec 31, 2023 | 59.55B | -41.62B | -41.14% |
| Dec 31, 2022 | 101.18B | 19.89B | 24.46% |
| Dec 31, 2021 | 81.29B | 39.64B | 95.16% |
| Dec 31, 2020 | 41.65B | 746.00M | 1.82% |
| Dec 31, 2019 | 40.91B | 80.00M | 0.20% |
| Dec 31, 2018 | 40.83B | -11.72B | -22.31% |
| Dec 31, 2017 | 52.55B | -278.00M | -0.53% |
| Dec 31, 2016 | 52.82B | 3.97B | 8.13% |
| Dec 31, 2015 | 48.85B | -754.00M | -1.52% |
| Dec 31, 2014 | 49.61B | -1.98B | -3.84% |
| Dec 31, 2013 | 51.58B | -3.07B | -5.62% |
| Dec 31, 2012 | 54.66B | -6.38B | -10.45% |
| Dec 31, 2011 | 61.04B | -4.13B | -6.34% |
| Dec 31, 2010 | 65.17B | 15.90B | 32.26% |
| Dec 31, 2009 | 49.27B | 973.00M | 2.01% |
| Dec 31, 2008 | 48.30B | -122.00M | -0.25% |
| Dec 31, 2007 | 48.42B | 47.00M | 0.10% |
| Dec 31, 2006 | 48.37B | 966.00M | 2.04% |
| Dec 31, 2005 | 47.41B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
PFE News
- 5 hours ago - Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry - CNBC
- 11 hours ago - Novavax enters license agreement with Pfizer for vaccine development - Reuters
- 15 hours ago - Japan's Shionogi boosts ViiV stake to 21.7% as Pfizer exits - Reuters
- 22 hours ago - Invesco Equity And Income Fund Q4 2025 Portfolio Positioning And Performance - Seeking Alpha
- 1 day ago - MoneyShow's Best Investment Ideas For 2026: Part 7 - Seeking Alpha
- 4 days ago - Pfizer: Rebound Has Just Started - Seeking Alpha
- 5 days ago - Pfizer: The Most Intriguing Value Play Of 2026 - Seeking Alpha
- 7 days ago - Pfizer's Patent Cliff, Rising Debt, And The Fight To Stay A Buy - Seeking Alpha